Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results. Health Serv Res 2011 Dec;46(6pt1):1762-77
Date
07/28/2011Pubmed ID
21790588Pubmed Central ID
PMC3393031DOI
10.1111/j.1475-6773.2011.01296.xScopus ID
2-s2.0-81755184338 (requires institutional sign-in at Scopus site) 27 CitationsAbstract
OBJECTIVE: In 1999, three randomized controlled trials concluded that high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HDC/HCT) is no better than conventional chemotherapy for women with breast cancer. This study documents the impact of the trials on use of HDC/HCT and describes how hospitals reacted to the trials.
DATA SOURCE: We used patient-level data on 15,847 HDC/HCTs reported to the Center for International Blood and Marrow Transplant Research between 1994 and 2005.
STUDY DESIGN: We report trends in total HDC/HCT procedure volume, compare the time to hospitals' exit from the HDC/HCT market between research and nonresearch hospitals, and document trends in hospital-specific volumes in the 2 years before exit.
PRINCIPAL FINDINGS: HDC/HCT volume declined from 3,108 in 1998 to 1,363 the year after trial results were released. In 2002, only 76 procedures were performed. Teaching hospitals and the hospitals that participated in the trials were no slower to discontinue the procedure compared with nonteaching, nonparticipating hospitals. At the hospital level, volume declined steadily in the months before abandonment.
CONCLUSION: The results suggest that comparative effectiveness research studies that report negative results can reduce spending, but specialists may be reluctant to relinquish cutting-edge technologies.
Author List
Howard DH, Kenline C, Lazarus HM, Lemaistre CF, Maziarz RT, McCarthy PL Jr, Parsons SK, Szwajcer D, Douglas Rizzo J, Majhail NSAuthor
J. Douglas Rizzo MD, MS Director, Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antineoplastic AgentsBreast Neoplasms
Combined Modality Therapy
Comparative Effectiveness Research
Female
Hematopoietic Stem Cell Transplantation
Humans
Information Dissemination
Practice Patterns, Physicians'
Randomized Controlled Trials as Topic